Stryker (NYSE:SYK) Stock Rating Upgraded by Barclays

Key Points

• Barclays upgraded Stryker to “strong buy,” while broader analyst coverage remains favorable with a consensus “moderate buy” rating and an average price target of $370.68.
• Stryker shares opened at $275.17, down 1.1%, near their 52-week low of $267 and below their 50-day and 200-day moving averages.
• The company recently exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, with revenue up 9.4% year over year; however, insiders have sold about $118.2 million of stock over the past 90 days.

Stryker (NYSE:SYK - Get Free Report) was upgraded by analysts at Barclays to a "strong-buy" rating in a research report issued to clients and investors on Wednesday, Zacks reports.

SYK has been the subject of a number of other research reports. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. BTIG Research dropped their target price on shares of Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a report on Friday, July 31st. Raymond James Financial set a $370.00 price target on shares of Stryker in a report on Friday, July 31st. Wells Fargo & Company lowered their price target on Stryker from $418.00 to $348.00 and set an "overweight" rating on the stock in a research report on Wednesday, September 9th. Finally, Royal Bank Of Canada dropped their price objective on Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $370.68.

Stryker Stock Down 1.1%

SYK stock opened at $275.17 on Wednesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker has a 1 year low of $267.00 and a 1 year high of $392.55. The company has a fifty day simple moving average of $306.83 and a 200 day simple moving average of $315.02. The firm has a market cap of $105.55 billion, a PE ratio of 28.51, a PEG ratio of 1.76 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The business's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker will post 14.97 EPS for the current fiscal year.

Insider Activity

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the business's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company's stock.

Institutional Trading of Stryker

A number of hedge funds have recently modified their holdings of SYK. Gables Capital Management Inc. acquired a new stake in Stryker during the second quarter worth $25,000. Kilter Group LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $25,000. Highland Investment Advisors LLC bought a new position in shares of Stryker during the 2nd quarter worth about $25,000. Cornerstone Financial Management LLC lifted its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock worth $25,000 after acquiring an additional 31 shares during the period. Finally, Sankala Group LLC acquired a new stake in shares of Stryker during the 4th quarter valued at about $26,000. Institutional investors own 77.09% of the company's stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Current President and COO Spencer Stiles will succeed Kevin Lobo as CEO on January 1, 2027, while Lobo becomes executive chair. The planned succession provides continuity because Stiles is an established internal leader familiar with Stryker’s operations and strategy. Stryker announces leadership succession
• Positive Sentiment: Needham said Stiles is a known entity to investors and well prepared to lead the company, supporting the view that the transition should not materially disrupt execution. Needham comments on Stiles
• Positive Sentiment: Truist also described the CEO change as low-risk, suggesting investor concerns may be manageable even though it reduced its price target to $310. Truist CEO transition commentary
• Neutral Sentiment: Coverage has focused on whether the leadership change will affect Stryker’s long-term growth and valuation relative to medical-device peers. A comparison with Boston Scientific noted that both stocks have weakened substantially, while Boston Scientific has higher margins. Stryker versus Boston Scientific
• Negative Sentiment: Investors initially reacted cautiously to the CEO announcement, likely reflecting uncertainty over replacing Lobo after his long tenure. The stock’s broader weakness and Truist’s lower price target reinforce near-term valuation concerns. Why Stryker dropped
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of Stryker investors. Such notices can add sentiment and headline risk, although the announcement does not establish wrongdoing. Pomerantz investor investigation

Stryker Company Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.

Stryker's product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.